Proprietary TAT Phospholipid Conjugate Demonstrates Potent Activity in Resistant Pancreatic Cancer Initiating IND-enabling Studies for First-in-Human Phase I Clinical Study FLORHAM PARK, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced promising preclinical data for its proprietary novel alpha-emitting phospholipid radiotherapeutic conjugate, CLR 121225 (225Ac-CLR 121225) an actinium-labeled phospholipid ether (PLE), in pancreatic cancer models.

专有的TAT磷脂缀合物在耐药性胰腺癌中显示出有效的活性，启动了IND研究，首次在人类I期临床研究中进行研究，新泽西州弗洛勒姆公园，2024年1月16日（环球新闻网）——Cellectar Biosciences，Inc.（纳斯达克：CLRB），一家专注于这一发现的晚期临床生物制药公司，用于治疗癌症的药物的开发和商业化，今天宣布了其专有的新型α-发射磷脂放射治疗缀合物CLR 121225（225Ac CLR 121225）（一种锕标记的磷脂醚（PLE））在胰腺癌模型中的有希望的临床前数据。

The development of this compound will expand the company’s clinical pipeline of PLE cancer targeting compounds to include targeted alpha therapies (TATs), complementing its beta-emitting phospholipid radiotherapeutic conjugate, iopofosine I 131, which achieved its primary endpoint in the CLOVER WaM pivotal study in highly refractory Waldenstrom’s macroglobulinemia patients.

该化合物的开发将扩大该公司的PLE癌症靶向化合物的临床管道，以包括靶向α疗法（TATs），补充其β发射磷脂放射治疗缀合物iopofosine I 131，该缀合物在三叶草WaM关键研究中实现了其主要终点。高度难治性Waldenstrom巨球蛋白血症患者。

Cellectar’s PLE platform may provide unique advantages which overcome the issues experienced by existing TAT delivery platforms. While current TAT platforms, such as antibodies and peptides, possess the potential to be effective for treating cancers with low tumor volume, they are challenged to treat higher volume or bulky tumors due to insufficient penetration and the need for high quantities of the target epitope.

Cellectar的PLE平台可以提供独特的优势，克服现有TAT交付平台遇到的问题。虽然目前的TAT平台，如抗体和肽，具有有效治疗肿瘤体积小的癌症的潜力，但由于渗透不足和需要大量靶表位，它们面临治疗体积较大或体积较大的肿瘤的挑战。

Cellectar’s PLE’s possess biochemical properties that enable penetration of the TAT payload deep into the tumor mass and the abundance of lipid rafts on tumor cells provides near universal delivery and enhanced outcomes. “The advancement of our TAT program is part of our overall strategy to develop a comprehensive portfolio of first- and best-in-class .

Cellectar的PLE具有生化特性，使TAT有效载荷能够深入肿瘤块，肿瘤细胞上丰富的脂筏提供了近乎普遍的递送和增强的结果。“TAT计划的推进是我们整体战略的一部分，旨在开发一流和一流的综合投资组合。